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AbstrACt
Objectives Professional paediatrics associations play 
an important role in promoting the highest standard of 
care for women and children. Education and guidelines 
must be made in the best interests of patients. Given the 
importance of breastfeeding for the health, development 
and survival of infants, children and mothers, paediatric 
associations have a particular responsibility to avoid 
conflicts of interest with companies that manufacture 
breast-milk substitutes (BMSs). The objective of this 
study was to investigate the extent to which national and 
regional paediatric associations are sponsored by BMS 
companies.
Methods Data were collected on national paediatric 
associations based on online searches of websites and 
Facebook pages. Sites were examined for evidence of 
financial sponsorship by the BMS industry, including 
funding of journals, newsletters or other publications, 
conferences and events, scholarships, fellowship, grants 
and awards. Payment for services, such as exhibitor space 
at conferences or events and paid advertisements in 
publications, was also noted.
results Overall, 68 (60%) of the 114 paediatric 
associations with a website or Facebook account 
documented receiving financial support from BMS 
companies. Sponsorship, particularly of conferences or 
other events, was the most common type of financial 
support. The prevalence of conference sponsorship is 
highest in Europe and the Americas, where about half 
of the associations have BMS company-sponsored 
conferences. Thirty-one associations (27%) indicated that 
they received funding from BMS companies as payment 
for advertisements or exhibitor space. Only 18 associations 
(16%) have conflict of interest policies, guidelines, or 
criteria posted online.
Conclusion Despite the well-documented importance 
of breastfeeding and the widespread recognition that 
commercial influences can shape the behaviours of 
healthcare professionals, national and regional paediatric 
associations commonly accept funding from companies 
that manufacture and distribute BMS. Paediatric 
associations should function without the influence of 
commercial interests.
IntrOduCtIOn/bACkgrOund
Breastfeeding is critical for the health, devel-
opment and survival of infants, children and 
mothers. Recent analyses have concluded 
that an estimated 820 000 infant and child 
deaths still occur each year from substan-
dard breastfeeding practices or non-breast-
feeding.1 Nearly half of diarrhoea episodes 
and one-third of respiratory infections are 
due to inadequate breastfeeding practices. 
Longer breastfeeding is associated with a 
13% reduction in the likelihood of over-
weight and obesity and a 35% reduction in 
the incidence of type 2 diabetes. An estimated 
20 000 maternal deaths from breast cancer 
could be prevented each year by improving 
breastfeeding. Economically, increasing rates 
of breastfeeding could add US$ 300 billion to 
the global economy annually by helping to 
foster smarter, more productive workers and 
leaders.2 
Marketing of breast-milk substitutes (BMSs) 
has effectively reduced rates of breastfeeding. 
strengths and limitations of this study
 ► This is the first study to systematically document the 
extent of conflicts of interest in national paediatric 
associations with regard to manufacturers of breast-
milk substitutes.
 ► Data from websites were available for 75% of na-
tional paediatric associations.
 ► Data were objectively collected and analysed based 
on online documentation.
 ► Funding that has not been documented on websites 
was not captured, potentially leading to an underes-
timate of the extent of industry funding.
 ► This study was not able to capture information on 
the amount of funding received or on how it com-
pares to funding from other sources.
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Globally, sales of BMSs are growing almost eight times as 
quickly as the world’s population.3 It is estimated that the 
six largest BMS manufacturers spend over US$7 billion 
annually on marketing activities.4 A significant portion 
of this marketing is targeted at healthcare providers 
and institutions. Given the importance of breastfeeding, 
health professional advice and support for breastfeeding 
should not be influenced by the commercial interests of 
BMS manufacturers.
The widespread involvement of BMS companies in 
healthcare has long been recognised and documented.5–7 
Recent studies in Mexico, Chile and Ecuador have 
reported extensive use of BMS promotional materials 
in health facilities, distribution of free formula samples, 
gifts to health workers, donations of equipment and 
sponsorship of events.8–10 In Bangladesh, many mothers 
are advised by healthcare workers, especially in private 
clinics, to use BMS without any prior counselling on 
breastfeeding.4 Health workers in China were paid by a 
BMS company to recommend infant formula to new or 
expectant mothers, leading to an US$12 million settle-
ment against the company.11
The International Code of Marketing of Breast-milk 
Substitutes, adopted by the World Health Assembly in 
1981, delineates a number of steps to limit the ways in 
which industry uses healthcare workers to promote its 
products.12 In 2005, the World Health Assembly urged 
countries to ‘ensure that financial support and other 
incentives for programmes and health professionals 
working in infant and young child health do not create 
conflicts of interest’.13 The 69th World Health Assembly 
(2016) passed a resolution on WHO’s ‘Guidance on 
ending inappropriate promotion of foods for infants and 
young children’, calling on health professionals to ‘fulfil 
their essential role in providing parents and other care-
givers with information and support on optimal infant 
and young child feeding practices and to implement the 
guidance recommendations’ (paragraph 4).14 The guid-
ance recommendations15 state that health professional 
associations should not ‘accept equipment or services 
from companies that market foods for infants and young 
children; accept gifts or incentives from such compa-
nies…[or] allow such companies to sponsor meetings of 
health professionals and scientific meetings’ (paragraph 
17). (The Implementation Manual16 for the Guidance 
provides more information).
Although anecdotal information exists about the rela-
tionship between the BMS industry and paediatric associ-
ations, it has not yet been examined in a systematic way. 
The objective of this study was to investigate the extent to 
which national and regional paediatric associations are 
sponsored by BMS companies.
MethOds
Data were collected on national (n=146) or regional 
(n=6) paediatric associations listed on the webpage of the 
International Paediatric Association.17
Online searches were conducted for evidence of 
funding of paediatric associations by the BMS industry. 
This involved first determining which associations had 
official websites or, in the absence of official websites, 
Facebook accounts. Searches were then conducted within 
the online presence for these associations. For associ-
ations with a website, searches were conducted on the 
main website, as well as any associated journal websites, 
conference websites, and charity or non-profit branch or 
foundation websites, as available.
In addition, the Facebook accounts of 10 
randomly selected associations that also had official 
websites were searched. As this process did not render 
any information in addition to that which was found on 
the website itself, no additional Facebook accounts were 
searched.
Table 1 Type of funding from breast-milk substitute 
(BMS) companies identified by online searches
Category Criteria
Sponsorship
  Funding of 
journals, 
newsletters or 
other publications
 ► Written indication of BMS 
companies as sponsors of the 
journal, magazine, or newsletter
  Funding for 
conferences and 
events
 ► BMS company logos on 
conference webpage
 ► Written indication of BMS 
companies as sponsors
 ► Written indication of satellite 
symposia or other events 
sponsored by BMS companies
  Funding for 
scholarships, 
fellowship, grants 
and awards
 ► Written indication of BMS 
companies as sponsors of 
scholarships, awards, grants, or 
fellowship funding
  Funding for 
websites or 
general use
 ► BMS company logos on home 
page or sponsors/partners page
 ► Written indication of BMS 
companies as sponsors
 ► Written promotion of a particular 
BMS company
Payment for services
  Paid 
advertisements in 
publications
 ► Advertisements of BMS 
companies in online publications
  Exhibitor space 
at conferences or 
events
 ► Written indication of BMS 
companies as exhibitors
 ► Photos of BMS exhibitions at 
conferences
Associations’ conflict 
of interest policies, 
guidelines or criteria
 ► Existence of any official document 
of the association that mentions 
conflicts of interest (includes 
official conflict of interest 
documents, codes of ethics, 
association statutes, etc.)
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Data were collected by two research assistants in 
June–August 2017. Reliability was assessed by having 
both research assistants conduct searches for the same 
10 member associations and compare results. Minor 
discrepancies were encountered as to where on the 
website certain information was encountered, but in no 
case was the overall assessment of receipt of funding 
from BMS companies different. After this process, the 
remaining associations were divided and assigned to 
each research assistant. Some websites were in a language 
that was familiar to one research assistant or the other 
and were therefore assigned accordingly. Websites in 
languages other than English, French, German, Italian, 
Portuguese or Spanish were translated using online 
translators and additional interpretation was sometimes 
provided by other WHO staff or interns. The rest were 
divided randomly.
The websites were examined for any logos or names 
of BMS companies found in acknowledgments, funding 
sources, advertisements and lists of exhibitors or spon-
sors of conferences. Where funders or sponsors were 
unknown, additional web searches were conducted to fully 
understand the nature of the donor. Home pages and all 
sub-pages, PowerPoint presentations, event photos and 
online documents, such as pamphlets, education sheets, 
newsletters and publicly accessible journals were included 
in the search. Content that required a membership to 
access, such as subscription journals, were not reviewed.
Searches were also conducted on the websites of BMS 
companies. Due to the high number of such companies 
(and national affiliates), it was impossible to identify or 
search the websites of all. In order to be systematic, the 
websites of ‘infant formula’ companies listed on the Baby 
Milk Action website were searched.18
Information was collected on the purpose of funding 
(table 1) and classified as either ‘sponsorship’ or ‘payment 
for services’. Funding was considered to be ‘sponsorship’ 
if there appeared to be no specific services provided to 
the donor other than acknowledgement. Funding was 
considered to be ‘payment for services’ if the paediatric 
association provided direct benefits to the company, such 
as through advertisements in a publication or exhibition 
space at a conference.
Data were entered into a spreadsheet and checked 
by both research assistants to verify the relevance of the 
information. For each category of funding, ‘sponsorship’ 
or ‘payment for services’, the association was counted as 
‘yes’ if there was evidence of financial contribution from 
BMS companies in that category. In addition to funding, 
information was collected on whether the association had 
policies or criteria on conflicts of interest available online.
Patient and public involvement
No patients were involved in the study.
results
Of the 152 paediatric associations, websites were identi-
fied for 109 and an additional five had Facebook pages, 
yielding a total of 114 associations with an online pres-
ence (75%). Overall, 68 of the paediatric associations 
with an online presence (60%) documented receipt of 
some kind of financial support from BMS companies, 
either in the form of sponsorship or payment for services 
(table 2). This was highest in the Americas region, with 23 
of 28 (82%) associations receiving some sort of funding 
from BMS companies. In Europe, 21 of 32 (66%) asso-
ciations received BMS funding, while in Asia and Africa 
it was 15 of 30 (50%) and 8 of 21 (38%), respectively. 
One association in Oceania was found to have received 
funding from BMS companies. However, there are only 
three paediatric associations identified in this region, and 
the results should be considered accordingly.
Table 2 Number of paediatric associations that receive financial support* from manufacturers of breast-milk substitutes 
based on website review, by type of support
World
(n=114)
Africa
(n=21)
Americas
(n=28)
Asia
(n=30)
Europe
(n=32)
Oceania
(n=3)
Any financial support n, (%) 68 (60%) 8 (38%) 23 (82%) 15 (50%) 21 (66%) 1 (33%)
Sponsorship n, (%) 60 (53%) 8 (38%) 20 (71%) 13 (43%) 19 (59%) 0 (0%)
  Funding of journals, newsletters or other publications 4 (4%) 0 (0%) 1 (4%) 3 (10%) 0 (0%) 0 (0%)
  Funding for conferences and events 43 (38%) 7 (33%) 13 (46%) 7 (23%) 16 (50%) 0 (0%)
  Funding for scholarships, fellowship, grants and 
awards
10 (9%) 0 (0%) 5 (18%) 3 (10%) 2 (6%) 0 (0%)
  Funding for websites or general use 15 (13%) 2 (10%) 5 (18%) 3 (10%) 5 (16%) 0 (0%)
  Purpose of funding not stated 16 (14%) 5 (24%) 7 (25%) 1 (3%) 3 (9%) 0 (0%)
Payment for services n, (%) 31 (27%) 1 (5%) 14 (50%) 5 (17%) 10 (31%) 1 (33%)
  Paid advertisements in publications 14 (12%) 1 (5%) 5 (18%) 3 (10%) 5 (16%) 0 (0%)
  Exhibitor space at conferences or events 22 (19%) 1 (5%) 10 (36%) 2 (7%) 8 (25%) 1 (33%)
*Financial support includes sponsorship, for which no specific services are provided to the donor other than acknowledgement, and 
payment for services.
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Sponsorship was the most common type of funding 
received by paediatric associations. Overall, 60 of 114 
(53%) websites of paediatric associations indicated 
sponsorship by BMS companies. Forty-three associations 
(38%) have conferences or other events sponsored by 
BMS companies. The prevalence of conference sponsor-
ship is highest in Europe and the Americas, where about 
half of the associations have BMS company-sponsored 
conferences.
In addition to conferences, paediatric associations may 
receive other types of sponsorship from BMS companies, 
though less frequently. Fifteen associations (13%) receive 
general sponsorship of the association or its website, 10 
associations (9%) receive sponsorship for scholarships, 
awards, grants or fellowships and 4 (4%) have publica-
tions that are sponsored.
Thirty-one associations (27%) indicated that they 
received funding from BMS companies as payment for 
services (eg, journal advertisements or exhibition space at 
conferences). This was highest in the Americas, with 14 of 
28 (50%), and in Europe, with 10 of 21 (31%). Fourteen 
(12%) were found to have BMS company advertising in 
their online publications (journals, magazines or newslet-
ters). Worldwide, only one-fifth (22 of 114) of the associa-
tions had exhibitions by the BMS industry at conferences.
Documentation of association sponsorship was also 
found on BMS company websites, although most of this 
information was captured on the association websites. 
While 16 associations were identified as recipients of 
funding on BMS company websites, only 3 of these asso-
ciations did not already have documentation of this 
on their own website. In general, it was not possible to 
determine the purpose of the sponsorship on the BMS 
company websites.
Only 18 (16%) associations published conflict of 
interest policies, guidelines or criteria. Many of these 
address conflicts of interest among individuals in lead-
ership positions or the need to declare interests when 
making presentations. Policies on sponsorship or funding 
typically gave general criteria that donors cannot compro-
mise the vision, mission or values of the association but 
did not specify how this would be determined. Two asso-
ciations listed specific industries that they would not work 
with (eg, tobacco and arms), but in neither case were 
BMS manufacturers on that list.
Associations that receive financial sponsorship from 
BMS companies are more likely to have a conflict of 
interest policy (13 of 60 associations, or 22%) than those 
that are not sponsored (5 of 54 associations, or 9%).
dIsCussIOn
Despite the well-documented importance of breastfeeding 
and the widespread recognition of how commercial influ-
ences shape the behaviours of healthcare professionals, 
national and regional paediatric associations commonly 
accept funding from companies that make BMS. This 
study found that 53% of association websites acknowledge 
receiving sponsorship from BMS companies. In addition, 
when payment for advertisements or exhibitor space is 
included, it can be seen that 60% of associations receive 
financial support from BMS companies.
A conflict of interest occurs when a set of conditions 
in which professional judgement concerning a primary 
interest (such as a patient’s welfare or the validity of 
research) tends to be unduly influenced by a secondary 
interest (such as financial gain).19 Rodwin20 defined it as 
when an individual has an obligation to serve a party or 
perform a role and the individual has either incentives or 
conflicting loyalties which encourage the individual to act 
in ways that breach his/her obligations.
Each type of sponsorship presents its own challenges 
and has the potential to create a conflict of interest. 
Perhaps of greatest concern is the widespread sponsor-
ship of conferences and other events at which paediatri-
cians meet and disseminate research. The impact of the 
BMS industry at these events—either as direct sponsors, 
sponsors of symposia or presenters of information—is 
not to be underestimated. For example, as Fabbri et al21 
noted, funding of conferences and satellite symposia may 
bias the scientific content presented at such events.
Furthermore, accepting any kind of support from the 
industry ‘creates a sense of obligation and loyalty to the 
company in question’.22 Even receiving foods and bever-
ages sponsored by industry at these events or receiving 
conference materials bearing company logos may cause 
physicians to feel a subconscious onus to reciprocate.23 
These factors have the potential to influence what physi-
cians prescribe to their patients.21 23 Exhibitions by the 
BMS industry at conferences are likewise concerning, 
particularly as participants are often required to walk 
through the exhibit hall to access scientific events.
Industry sponsorship of medical journals is concerning 
in that it may shape the content that is presented to health 
professionals. Funding for scholarships and grants has the 
potential to impact what topics are researched, thus influ-
encing the field for years to come.24 Recommendations 
on clinical practice may be unduly influenced by close 
relationships between professional expert bodies and the 
BMS industry. For example, van Tulleken25 has noted that 
prescriptions of specialist formula milks for cow’s milk 
protein allergy have increased dramatically over the past 
decade based on the guidelines of several expert groups. 
Ten of the 12 authors of the 2012 European Society for 
Paediatric Gastroenterology, Hepatology, and Nutrition 
guidelines on diagnosis and management of cow’s-milk 
protein allergy26 and all authors of the international Milk 
Allergy in Primary Care (iMAP) guideline on cow’s milk 
allergy27 declared financial interests with infant formula 
manufacturers.
This study was unable to document the actual amount 
of funding provided by the BMS companies, as this infor-
mation is rarely posted on public websites. Professional 
medical associations are not required to share their finan-
cial records.28 Dalsing24 has estimated that professional 
medical associations receive 30%–50% of their budgets 
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from industry relationships. Many associations are 
currently dependent on funding from BMS companies 
for operating expenses.
Although refusing sponsorship from the BMS industry 
may reduce paediatric associations’ budgets, there are 
alternatives that could lessen the impact of the financial 
relationships. Schofferman et al28 suggests that associa-
tions raise their dues, increase recruitment or downsize 
some of their more expensive activities. It has been esti-
mated that the American Academy of Pediatrics could 
raise its dues US$50 to cover the cost of refusing BMS 
sponsorship.29
Only 18 associations (16%) had posted online some 
sort of policy to manage conflicts of interest. Interestingly, 
associations with a conflict of interest policy are actually 
more likely to accept sponsorship from BMS companies 
than those that do not have such policies. This finding 
is consistent with previous research by Fabbri et al,21 
showing that Italian professional medical associations 
with a conflict of interest policy were no less likely to have 
sponsorship from industry as those without. It may be 
the case that conflict of interest policies actually make it 
easier to accept funding or it may be that once a decision 
has been made to accept funding, the association sees the 
need to write down a policy to justify the acceptance and 
to govern how the funds will be used.
strengths
This is the first time that the sponsorship of national and 
regional paediatric associations by BMS companies has 
been documented in a systematic way. Out of 152 known 
associations, we found online information about 114 of 
them, allowing for a regional breakdown of patterns. 
Data were objectively collected and analysed. We were 
able to document the purpose of the funding received 
and examine the existence and content of policies about 
funding and conflicts of interest.
limitations
As the research was limited to associations’ online pres-
ence, some information was likely missed. The asso-
ciations were not contacted directly to confirm the 
completeness of the website documentation. No informa-
tion was available for the 38 associations with neither a 
website nor Facebook page, although these associations 
were generally in small countries and may be quite small 
associations. Review of websites not in English, French, 
German, Italian, Portuguese or Spanish may not have 
been entirely complete. Not all funding may be acknowl-
edged on websites. It was outside of the scope of this 
project to investigate print versions of publications, which 
may be more likely to display advertisements than online 
versions of journals. As a result, the extent of industry 
funding is likely underestimated.
This study was not able to capture information on the 
amount of funding received or on how it compares to 
funding from other sources.
COnClusIOn
This study has documented that paediatric associations 
regularly receive funding from BMS companies, particu-
larly through sponsorship of conferences and meetings, 
as well as publications, scholarships, fellowship, grants 
and awards. Paediatric associations are tasked above all 
else with safeguarding the health of infants, children 
and mothers and promoting the highest standard of 
care, including the protection, promotion and support 
of breastfeeding. WHO recommends that this should be 
without influence from industry. Policies on conflicts of 
interest are relatively rare and do not appear to limit the 
decision to accept funds from the BMS industry. In accor-
dance with the World Health Assembly Resolution 69.9, 
paediatric associations should refuse sponsorship from 
the BMS industry and identify alternative funding models 
especially with respect to the management and style of 
conferences.
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